Ulta Beauty (ULTA) Form 4: Director awarded 277 RSUs vesting 2026
Rhea-AI Filing Summary
Ulta Beauty director Martin Brok received a grant of 277 restricted stock units (RSUs) on 09/01/2025, recorded as a non‑derivative acquisition at a grant price of $0. After the grant, the reporting person beneficially owned 1,277 shares of Ulta Beauty common stock in a direct form. The RSUs vest 100% on 09/01/2026, per the form's explanation. The Form 4 was filed by a single reporting person and signed by an attorney‑in‑fact on 09/03/2025. This disclosure documents a routine equity compensation award to a director and the resulting change in direct beneficial ownership.
Positive
- None.
Negative
- None.
Insights
TL;DR: Small, routine director equity grant — immaterial to financials but aligns interests with shareholders.
The Form 4 reports a grant of 277 RSUs to Director Martin Brok on 09/01/2025, vesting fully on 09/01/2026 and recorded at $0 paid. The post‑transaction direct beneficial ownership is 1,277 shares. From a financial perspective, this transaction reflects standard equity compensation and is unlikely to affect Ulta Beauty's reported results or outstanding share count until vesting and delivery occur. It signals continued use of equity incentives for non‑employee directors rather than cash, which modestly aligns director incentives with shareholder outcomes.
TL;DR: Routine governance disclosure showing director compensation via RSUs with a one‑year vesting schedule.
The filing documents compliance with Section 16 reporting requirements for a director award: 277 restricted stock units granted 09/01/2025, vesting 09/01/2026. The Form 4 was filed by one reporting person and signed by an attorney‑in‑fact on 09/03/2025. This is a standard disclosure showing transparency of insider holdings and timing of equity award vesting; there is no indication of accelerated vesting, transfers, or derivative transactions in this filing.